Overview

  • Product nameHonokiol
  • Description
    Anti-inflammatory and chemotherapeutic agent
  • Biological descriptionPotent scavenger of reactive oxygen species with antiangiogenic, antitumor and anti-inflammatory properties. Mechanisms of action include inhibition of ras signalling and activation of the mitochondrial transistion pore via cyclophilin D induction. Inhibits NF-κB signaling, upstream of VEGF. Blood brain barrier permeable.
  • Purity> 98%

Properties

    Applications

    Our Abpromise guarantee covers the use of ab120647 in the following tested applications.

    The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

    Application Notes
    Functional Studies Use at an assay dependent concentration.

    Honokiol images

    • MCF7 cells were incubated at 37°C for 6h with vehicle control (0 µM) and different concentrations of honokiol(ab120647). Increased expression of acetyl coenzyme A carboxylase (phospho S79)(ab31931) in MCF7 cells correlates with an increase in honokiol concentration, as described in literature.

      Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab31931 at 1 µg/ml and ab8227 at 1 µg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.

    • MCF7 cells were incubated at 37°C for 6h with vehicle control (0 µM) and different concentrations of honokiol(ab120647). Increased expression of AMPKα 1 + AMPKα 2 (phospho T172) (ab23875) in MCF7 cells correlates with an increase in honokiol concentration, as described in literature.

      Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10µg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab23875 at 1/1000 dilution and ab8227 at 1 µg/ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (ab97051) at 1/10000 dilution and visualised using ECL development solution.

    References for Honokiol (ab120647)

    This product has been referenced in:
    • Arora S  et al. Honokiol arrests cell cycle, induces apoptosis, and potentiates the cytotoxic effect of gemcitabine in human pancreatic cancer cells. PLoS One 6:e21573 (2011). Read more (PubMed: 21720559) »
    • Munroe ME  et al. Anti-inflammatory effects of the neurotransmitter agonist Honokiol in a mouse model of allergic asthma. J Immunol 185:5586-97 (2010). Read more (PubMed: 20889543) »
    • Fried LE & Arbiser JL Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal 11:1139-48 (2009). Read more (PubMed: 19203212) »

    See 0 Publications for this product

    Product Wall

    There are currently no Questions for ab120647.
    Please use the link above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"